Wu, J, Tomsa, D, Zhang, M, Komenda, P, Tangri, N, Rigatto, C, Lin, F.
ACS SensorsPublication Category Read More
Urinary albumin level is an important indicator of kidney damage in chronic kidney disease (CKD) but effective routine albumin detection tools are lacking. In this paper, we developed a low-cost and high accuracy microfluidic urinary albumin chip (UAL-Chip) to rapidly measure albumin in urine. The UAL-Chip offers three major features: (1) we incorporated a fluorescent reaction assay into the chip to improve the detection accuracy; (2) we constructed a passive and continuous mixing module in the chip that provides user-friendly operation and greater signal stability; (3) we applied a pressure-balancing strategy based on the immiscible oil coverage that achieves precise control of the sample-dye mixing ratio. We validated the UAL-Chip using both albumin standards and urine samples from 12 CKD patients and achieved an estimated limit of detection (LOD) of 5.2 ?g/mL. The albumin levels in CKD patients’ urine samples measured by UAL-Chip is consistent with the traditional well-plate measurements and clinical results. We foresee the potential of extending this passive and precise mixing platform to assess various disease biomarkers.
Prevalence, socio-demographic characteristics, and comorbid health conditions in pre-dialysis chronic kidney disease: results from the Manitoba chronic kidney disease cohort
Chartier, M, Tangri, N, Komenda, P, Walld, R, Koseva, I, Burchill, C, McGowan, K, Dart, A.
BMC NephrologyPublication Category Read More
Chronic Kidney Disease (CKD) is common and its prevalence has increased steadily over several decades. Monitoring of rates and severity of CKD across populations is critical for policy development and resource planning. Administrative health data alone has insufficient sensitivity for this purpose, therefore utilizing population level laboratory data and novel methodology is required for population-based surveillance. The aims of this study include a) develop the Manitoba CKD Cohort, b) estimate CKD prevalence, c) identify individuals at high risk of progression to kidney failure and d) determine rates of comorbid health conditions.
Beaudry, A, Ferguson, T, Rigatto, C, Tangri, N, Dumanski, S, Komenda, P.
Clinical Journal of the American Society of NephrologyPublication Category Read More
The prevalence of ESKD is increasing worldwide. Treating ESKD is disproportionately costly in comparison with its prevalence, mostly due to the direct cost of dialysis therapy. Here, we aim to provide a contemporary cost description of dialysis modalities, including facility-based hemodialysis, peritoneal dialysis, and home hemodialysis, provided with conventional dialysis machines and the NxStage System One.